Objective:
To evaluate the effect of bleeding episodes on hemophilia patient burden of illness using observational data.
Methods:
Between 2005-2007 and 2009-2012, the Hemophilia Utilization Group Studies Va…
Objective:
To assess the pharmacokinetics (PK) and efficacy of prophylactic treatment with BAX 855 - a novel polyethylene glycol (peg)ylated full-length recombinant factor VIII, built on the rAHF-PFM (ADVATE) protein - by age…
Prophylactic factor VIII (FVIII) replacement therapy in hemophilia A requires frequent administration because of the short half-life of FVIII. Polyethylene glycol (PEG) conjugation is thought to extend FVIII half-life by decreasing hepatic clearance…
Summer is a season filled with excitement and adventure, especially for children. It's a time when kids can immerse themselves in new experiences, make lifelong friendships, and create cherished memories.
For parents of children with bleeding…
Background:
BAY 1093884 is a fully human monoclonal antibody against tissue factor pathway inhibitor (TFPI) developed as a bypass agent for hemophilia patients with inhibitors. It restores thrombin burst for stable clot formation…
Objective:
Clinical knowledge gaps of hemophilia can affect patient outcomes through delayed diagnosis/referral as well as improper monitoring and interventions. A study was undertaken to identify and characterize clinical…
The U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA), announced $20 billion in new funding for providers on the frontlines of the coronavirus pandemic. Eligible providers may begin…
Attention healthcare providers!
There are three excellent online educational opportunities that can be completed for accreditation through October 31st – that’s less than 30 days from now so don’t delay!
All…